Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

603 - Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild type advanced NSCLC

Date

24 Nov 2018

Session

Poster display - Cocktail

Topics

Immunotherapy;  Translational Research

Presenters

Peng Xiao

Citation

Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425

Authors

P.X. Xiao1, R. Yu2, X. Wu2, Y.W. Shao2, Y. Wu3, Q. Zhou1

Author affiliations

  • 1 Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN
  • 2 Translational Medicine Research Institute, Geneseeq Technology Inc., M5G1L7 - Toronto/CA
  • 3 Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou/CN
More

Resources

Abstract 603

Background

Immunotherapy has become important treatment option for advanced NSCLC patients. Although many predictive biomarkers of immunotherapy are under exploring, such as PD-L1 expression level, tumor mutation burden, microsatellite instability and mismatch repair-deficient, they cannot fully meet the clinical demand, resulting in an urgent need for identifying novel biomarkers. Here, we explored the possibility of using plasma exosomal microRNAs as potential biomarkers for the optimal selection of advanced NSCLC patients to immunotherapy.

Methods

Plasma samples of 9 EGFR/ALK-wild type (WT) (confirmed by ARMS and IHC method) advanced NSCLC patients were collected before the administration of PD-1/PD-L1 inhibitors. The efficacy evaluation was conducted after 3 cycles of the treatment. Post-treatment plasmas were collected from 4 disease control (DC) patients (PR and SD). Plasma from 7 healthy individuals was collected as control. Exosomes were extracted by ultracentrifugation and exosomal miRNAs were analyzed by small RNA next-generation sequencing.

Results

Cancer patients' exosomal miRNA profiles can be distinguished from those in healthy individuals by PCA clustering, which post-treatment samples also tend to separate from pre-treatment samples. A total of 120 exosomal miRNAs were differentially presented in advanced NSCLCs compared to healthy individuals (FDR<0.01, p < 0.05 by exact test). Three miRNAs (miR-320d, miR-320c, miR-320b) from the miR320 family were identified differentially up-regulated in PD groups compared to DC patients and healthy individuals. In addition, we identified 311 differentially expressed exosomal miRNAs (111 up and 200 down-regulated) in post-treatment samples compared to pre-treatment samples, including down-regulated miR-125b-5p (a γβ T cell suppressor), miR-1246 and miR-1290, as well as up-regulated miR-4433b and miR-744-5p. Based on the results, these miRNAs may serve as predictive biomarkers for immunotherapy.

Conclusions

Cancer patients' exosomal miRNA profile differs from healthy individuals. The baseline profile of plasma exosomal microRNAs and its dynamic change might be correlative with the efficacy of immunotherapy in EGFR/ALK wild type advanced NSCLC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Guangdong Lung Cancer Institute.

Funding

Has not received any funding.

Disclosure

R. Yu, X. Wu: Employee: Geneseeq Technology Inc. Y.W. Shao: Shareholder: Geneseeq Technology Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.